Wednesday, March 29, 2023 3:29:22 PM
The proof is in the data.
Up to 49.4% of patients treated with XPHOZAH monotherapy or XPHOZAH in combination with sevelamer achieved a sP level within the normal range during the 18-month treatment period, which is 66.3% better than standard of care, at 29.7%, as shown in DOPPS February 2021
https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-presents-positive-data-further-supporting-efficacy-and
This data is important. As there are many other drugs for the treatment of hyperphosphatemia. But having an additional option for patients is important. What works for some may not work for others.
Accumulation. Those bars are getting really big.
Recent ARDX News
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
